Opimet-G Tablet SR is a combination oral antidiabetic medication containing Gliclazide 80 mg and Metformin 500 mg, formulated to provide sustained release for improved glycemic control in patients with type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels, while Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. The sustained-release formulation ensures a gradual and prolonged drug release, minimizing peak plasma concentrations and reducing the risk of hypoglycemia and gastrointestinal side effects commonly associated with immediate-release formulations. Opimet-G Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. Patient counseling should emphasize adherence to prescribed dosage, lifestyle modifications, and recognition of hypoglycemia symptoms. Regular renal function assessment is recommended during therapy to ensure safe use.